Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Reporter Virgin Islands.
Press releases published on April 25, 2025
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
GlobeNewswire
·
April 25, 2025
FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees …
Rezolute, Inc. Announces Closing of Underwritten Offering
GlobeNewswire
·
April 25, 2025
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing …
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
GlobeNewswire
·
April 25, 2025
FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and …
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
GlobeNewswire
·
April 25, 2025
SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared at the American Association for Cancer Research (AACR) …
Prelude Announces Presentations at 2025 AACR Annual Meeting
GlobeNewswire
·
April 25, 2025
Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and develop selective KAT6A degraders, …
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
GlobeNewswire
·
April 25, 2025
IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications …
Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development
GlobeNewswire
·
April 25, 2025
HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Spanios, a leader in human-derived organoid model systems, is pleased to announce a strategic partnership with White Lion Capital LLC. This collaboration empowers biotech and pharma companies to leverage Spanios’ …
Tevogen Bio Announces 2025 Annual Meeting
GlobeNewswire
·
April 25, 2025
WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual Meeting”) via live webcast at 11 a.m. …
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
GlobeNewswire
·
April 25, 2025
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model …
Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 25, 2025
PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today the presentation of positive data …
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
GlobeNewswire
·
April 25, 2025
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity - Combination …
T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting Demonstrating a Potential Best-in-Class PRAME Targeted TCR-T Therapy
GlobeNewswire
·
April 25, 2025
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat …
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
GlobeNewswire
·
April 25, 2025
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April …
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
GlobeNewswire
·
April 25, 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines BDC-3042 showed …
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
GlobeNewswire
·
April 25, 2025
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage …
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
GlobeNewswire
·
April 25, 2025
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kinase …
Enable Injections Presents Survey Results Highlighting Missed Opportunities in Subcutaneous Oncology Drug Development at AACR 2025
GlobeNewswire
·
April 25, 2025
CINCINNATI, April 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse® wearable drug delivery platform, announced today the presentation of a poster featuring new findings …
Towards the Light: Co-creating a New Global Journey in the AI Field — The Grand 2025 AI Intelligent Development Summit
GlobeNewswire
·
April 25, 2025
Hong Kong, April 25, 2025 (GLOBE NEWSWIRE) -- On April 22, 2025, the "Towards the Light: Co-creating a New Global Journey in the AI Field — 2025 AI Intelligent Development Summit" grandly opened at the Hop Hing Hotel in Hong Kong, China. This forum focused …
American Rebel CEO Andy Ross Harnesses Media Appearance on NBC-TV West Palm Beach Affiliate to Amplify Growth Strategy, Propel Brand Expansion and Launch American Rebel Light Beer in Florida
GlobeNewswire
·
April 25, 2025
From Song to Strategy: American Rebel's CEO Andy Ross Shares the Brand's Journey with Sunshine Spotlight Host Fiona Daghir Detailing the Journey of America’s Patriotic Brand to Becoming the Next Great American Success Story. West Palm Beach, FL, April 25, …
Ov Finance Upgrades Blockchain Infrastructure to Deliver Faster, Safer Digital Asset Trading
GlobeNewswire
·
April 25, 2025
Atlanta, GA, April 25, 2025 (GLOBE NEWSWIRE) -- Ov Finance, a financial technology and cryptocurrency company, has announced a major upgrade to its blockchain infrastructure aimed at boosting platform performance, enhancing security, and enabling seamless …